Alnylam Pharmaceuticals
Nasdaq ALNY · Cambridge, MA
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Alnylam Pharmaceuticals is a clinical trial sponsor based in Cambridge, MA, listed as Nasdaq ALNY. It has 26 active clinical trials with 19,736 planned participants, across 15 therapeutic areas. Since 2021 it has completed 23 trials and stopped 6 early.
Trial track record · since 2021
Financials · Nasdaq ALNY
Pipeline · 26 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
4 approved drug applications with a product on the market.
Questions about Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is lead sponsor of 26 active clinical trials on ClinicalTrials.gov, with 19,736 planned participants, in Cardiovascular, Dermatology, ENT, Genetic & rare and other areas. Since 2021 it has completed 23 trials and stopped 6 early.
Alnylam Pharmaceuticals is based in Cambridge, MA and is listed as Nasdaq ALNY. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Alnylam Pharmaceuticals; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-15.
Approve Suite is not affiliated with Alnylam Pharmaceuticals. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.